San Francisco Bay Area biotech stories.
Tuesday, February 22, 2011
Gilead to buy Calistoga Pharmaceuticals for $375M
Glead Sciences Inc. has agreed to acquire Calistoga Pharmaceuticals Inc. for $375 million, the companies said Tuesday.
Calistoga could earn up to an additional $225 million if certain milestones are achieved.
Seattle-based Calistoga is a privately held biotech company focused on the development of medicines to treat cancer and inflammatory diseases.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)